Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain from G-CSF in Adults with Blood Cancers

What this Trial Is About

Researchers are evaluating the best way to prevent bone pain caused by G-CSF Granulocyte Colony-Stimulating Factor in adults with blood cancers such as leukemia and lymphoma. This interventional study compares two oral medicationsdiosmin-hesperidin, a flavonoid supplement, and loratadine, a common anti-allergy drugalong with their combination, to see which is more effective at preventing this common and painful side effect of G-CSF treatment. Participants will be randomly assigned to one of four groups a control group receiving no specific preventive treatment, a loratadine group taking 10 mg once daily, a diosmin-hesperidin group taking 500 mg twice daily, or a combination group taking both medications. All treatments begin 30 minutes before filgrastim administration and continue for 5 days. Filgrastim will be given according to standard care for their hematological condition. Participants will undergo baseline assessments including medical history, laboratory tests, and pain evaluation before starting filgrastim. Pain and serum TNF-alpha levels will be measured 24 hours after the first filgrastim dose and again after 5 days of treatment. Researchers will monitor changes in bone pain severity and interference, aiming to identify which medication or combination best prevents G-CSF-induced bone pain. The total participation spans the treatment and follow-up assessments over these 5 days.

Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers